Rangeley Capital LLC Purchases New Shares in uniQure (NASDAQ:QURE)

Rangeley Capital LLC acquired a new position in uniQure (NASDAQ:QURE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 16,700 shares of the biotechnology company’s stock, valued at approximately $295,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. RTW Investments LP bought a new position in shares of uniQure in the third quarter valued at approximately $49,000. Quarry LP purchased a new position in uniQure in the third quarter worth $58,000. Twin Tree Management LP bought a new position in uniQure in the 4th quarter valued at $77,000. FNY Investment Advisers LLC purchased a new stake in shares of uniQure during the 4th quarter valued at $88,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 969 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on QURE shares. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of uniQure in a research report on Tuesday, March 4th. Wells Fargo & Company decreased their price objective on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Leerink Partners upped their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. Finally, Stifel Nicolaus upped their price target on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.80.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 26,727 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $285,978.90. Following the completion of the transaction, the chief executive officer now owns 571,188 shares of the company’s stock, valued at approximately $6,111,711.60. This trade represents a 4.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the transaction, the chief financial officer now owns 155,168 shares of the company’s stock, valued at $1,756,501.76. The trade was a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock worth $961,401 in the last three months. 4.74% of the stock is owned by corporate insiders.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $10.62 on Thursday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market cap of $574.30 million, a price-to-earnings ratio of -2.14 and a beta of 0.37. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a 50-day moving average price of $13.50 and a 200-day moving average price of $10.89.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.